Potassium Bicarbonate
drugOn this page
Also known as ArmicarbCarbonic acidmonopotassium saltE-501(II)INS NO.501(II)INS-501(II)KafyloxKaligreenKhco3MilstopPot effPotassium carbonate solutionPotassium hydrogencarbonatePurple k
Summary
Potassium Bicarbonate (CHEMBL2106975) is an approved small-molecule raising agent (ATC A12BA04); indicated across 1 condition including nephrolithiasis.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: A12BA04
- Indications: 1 condition
- Clinical trials: 8
- Chemistry: 100.115 Da · CHKO3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2106975 |
| Name | Potassium Bicarbonate |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 516893 |
| ChEBI | CHEBI:81862 |
| ATC | A12BA04 |
| Molecular formula | CHKO3 |
| Molecular weight | 100.115 |
| InChIKey | TYJJADVDDVDEDZ-UHFFFAOYSA-M |
SMILES: C(=O)(O)[O-].[K+]
IUPAC name: potassium hydrogen carbonate
ChEBI definition: A potassium salt that is the monopotassium salt of carbonic acid. It has fungicidal properties and is used in organic farming for the control of powdery mildew and apple scab.
Pharmacological roles (ChEBI): raising agent, antifungal agrochemical.
Other ChEBI roles (chemical / environmental): food acidity regulator, buffer.
Also known as: Armicarb, Carbonic acid, monopotassium salt, E-501(II), INS NO.501(II), INS-501(II), Kafylox, Kaligreen, Khco3, Milstop, Pot eff, Potassium bicarbonate
Patent coverage: 64,962 distinct patent families (163,426 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 138,444 (85%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| nephrolithiasis | 0 | MONDO:0008171 | EFO:0004253 |
Clinical trials
Total trials: 8.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 6 |
| PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01475214 | PHASE2 | COMPLETED | Musculoskeletal Effects of Bicarbonate |
| NCT04651088 | EARLY_PHASE1 | NOT_YET_RECRUITING | Comparing Alkalinizing Agents Efficacy on Stone Risk in Patients on a Metabolically Controlled Diet |
| NCT00357214 | Not specified | COMPLETED | Effect of Potassium Bicarbonate Supplementation on Bone and Muscle in Older Adults |
| NCT00730184 | Not specified | COMPLETED | Does Potassium Bicarbonate Improve the Effect of Dietary Protein on Bone and Muscle? |
| NCT01509456 | Not specified | COMPLETED | The Effect of Potassium Bicarbonate on Bone and Several Physiological Systems During Immobilisation |
| NCT01655953 | Not specified | COMPLETED | Changes in Acid Base Status During High Salt Intake |
| NCT01655979 | Not specified | COMPLETED | Medium-term Bedrest Whey Protein (MEP) |
| NCT04048616 | Not specified | COMPLETED | Impact of Protein and Alkali Supplementation on Skeletal Muscle in Older Adults |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.